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It is becoming increasingly common for pharmaceu-
tical companies to submit pharmacoeconomic stud-
ies to national and local agencies when applying for
inclusion of drugs on formularies or approved lists
for reimbursement. In some cases pharmacoeco-
nomic data are submitted to government agencies,
such as the National Institute for Clinical Excel-
lence (NICE) in the UK or the Pharmaceutical Ben-
eﬁts Advisory Committee in Australia. In other
cases they are submitted, on request, to managed
care groups or hospital formulary committees. Eco-
nomic evaluations and/or studies of resource impli-
cations are also increasingly published on clinical
practice guidelines web sites, by agencies such as the
Scottish Intercollegiate Guidelines Network and the
New Zealand Guidelines Group.
When data are submitted, they are often desig-
nated as “commercial-in-conﬁdence,” meaning that
they are made available to the agency concerned for
the purpose of reaching its decision, but are not to
be released to a third party [1].
There are a number of commercial and other rea-
sons why companies might designate data to be
“commercial-in-conﬁdence.” The price of the drug
is, of course, required for an assessment of cost-
effectiveness and the release of details of the com-
pany’s price expectations prior to commercial
availability may be damaging. Also, the company’s
submission could contain unpublished clinical data,
details of clinical development plans, or clues about
market positioning, knowledge of which could help
a competitor company prepare its market response.
Finally, the analytic methods employed in a com-
pany submission, especially any decision-analytic
model, could be viewed as commercial-in-
conﬁdence.
In addition to the commercial reasons for desig-
nating data to be “commercial-in-conﬁdence,” there
are also academic reasons relating to publication of
the pharmacoeconomic analysis in a peer-reviewed
journal. Prior release of details of the methods or
results of the pharmacoeconomic study by the deci-
sion-making agency could threaten publication
plans because the decision-making agency may wish
to make some of the data or methods publicly avail-
able in order to explain its decision. This is partic-
ularly important for public agencies because they are
often under considerable pressure to make their
decision-making procedures more transparent. For
example, in the United Kingdom, NICE attempts to
make as much information as possible available on
its web site. This includes the technology assessment
reports commissioned from academic groups and
the drafts of the Institute’s guidance.
The technology assessment reports frequently
contain summaries of the company submissions,
although commercial-in-conﬁdence information is
“stripped out” of the public version. Sometimes this
makes the reports difﬁcult to follow. The Institute’s
guidance usually contains a summary of the head-
line results of the studies submitted by companies
and, on occasions, NICE seeks permission from the
companies concerned to cite information that was
previously designated as commercial-in-conﬁdence.
The possible release, by decision-making agen-
cies, of details of study methods, or headline results,
of company-sponsored pharmacoeconomic studies
has raised concerns that it will not be possible to
publish in journals at a later date. Therefore, we
would like to clarify the editorial practices followed
by Value in Health that deal with this situation, as
well as with related situations such as public release
of pharmacoeconomics information by national
clinical guidelines agencies. These practices are out-
lined below.
Value in Health is pleased to review papers that
present estimates of the value of health care inter-
ventions and that have been derived using sound
methodology and credible data sources. The deci-
sion on publication of these papers depends on ini-
tial editorial review, then peer review, and a ﬁnal
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editorial decision based on the peer review. Previous
public dissemination of the methods, data sources,
and results of the study in a poster or podium pres-
entation at a professional meeting will not preclude
publication in Value in Health. In addition, posting
of the methods, data sources, and/or results on a
national or local decision maker’s Web site as sup-
port for their reimbursement decision or their
national clinical guidelines will not preclude publi-
cation in Value in Health. However, publication of
the same information in another professional jour-
nal, whether in the same language or in another lan-
guage, will generally preclude publication in Value
in Health.
Value in Health encourages authors of economic
evaluations of health care interventions to submit
their studies to our journal. Our editorial policies
leave the authors free to allow the dissemination of
economic evaluations at professional meetings and
by decision makers to their constituents on their
Web sites as part of their clinical guidelines or their
rulings on reimbursement for a new intervention.
We hope that this clariﬁcation of the Value in
Health editorial policies will reduce the extent to
which economic evaluations submitted to health
care authorities are designated commercial-in-
conﬁdence. The source data for health care deci-
sions, both clinical guidelines and reimbursement,
should be publicly available to allow for trans-
parency and public accountability for such
decisions.
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